Results 81 to 90 of about 12,367 (201)

A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel. [PDF]

, 2019
Pexidartinib (PLX3397) is a small molecule tyrosine kinase and colony-stimulating factor-1 inhibitor with FDA breakthrough therapy designation for tenosynovial giant-cell tumor, and currently under study in several other tumor types, including breast ...
Chien, A Jo, Esserman, Laura J, Hyland, Colby, Piawah, Sorbarikor, Rugo, Hope S, Umetsu, Sarah E   +5 more
core  

Characterization of amoxicillin‐ and clavulanic acid‐specific T cells in patients with amoxicillin‐clavulanate–induced liver injury [PDF]

, 2015
Drug‐induced liver injury (DILI) frequently has a delayed onset with several human leukocyte antigen (HLA) genotypes affecting susceptibility, indicating a potential role for the adaptive immune system in the disease.
Abajo, Bomarrito, Britschgi, Cavani, Daly, Danan, Donaldson, Fontana, Jenkins, Kindmark, Li, Lucena, Lucena, Maria, Mauri-Hellweg, Metushi, Monshi, Mudnakudu Nagaraju, Naisbitt, Nattrass, O'Donohue, Pichler, Pichler, Sabat, Schaid, Singer, Spraggs, Stephens, Wu, Wu, Wuillemin, Wuillemin, Yanaba, Yanaba   +33 more
core   +1 more source

Efek Pemberian Metilprednisolon Oral Terhadap Gambaran Histopatologik Hati Tikus Wistar (Rattus Norvegicus) [PDF]

, 2016
: Drug-induced liver injury (DILI) is an adverse drug reaction which vary in its clinical manifestations, ranging from an asymptomatic increase in liver enzymes to fulminant hepatic failure.
Durry, M. F. (Meilany), Lintong, P. M. (Poppy), Rifaldi, M. (Muhammad)   +2 more
core  

Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy [PDF]

, 2016
Aim: Drug-induced liver injury is one of the most serious adverse drug reactions and the most frequent reason for restriction of indications or withdrawal of drugs. Some nonsteroidal anti-inflammatory drugs (NSAIDs) were withdrawn from the market because
Arzenton, E., Bonaiuti, R., Bortolami, O., Capuano, A., Conforti, A., Donati, M., Lenti, M.C., Leone, R., Moretti, U., Motola, D., Rafaniello, C., Sportiello, L., Vaccheri, A., Vannacci, A.   +13 more
core   +2 more sources

Natural history and outcomes in drug induced autoimmune hepatitis [PDF]

, 2016
Aim: Drug-induced autoimmune hepatitis (DIAIH) remains poorly characterized. Our aim was to assess natural history and outcomes in DIAIH. Methods: This was a retrospective cohort study.
Alla, Alvarez, Andrade, Appleyard, Björnsson, Björnsson, Björnsson, Castiella, Castiella, Cohen, Danan, Feld, Heneghan, Heurgué, Kennedy, Kocman, Lawrenson, Licata, Lucena, MacGregor, Manns, Navarro, Roberts, Russo, Sakaan, Scully, Sharp, Shepherd, Sugimoto, Suzuki, Unzueta, Verma, Verma, Weiler-Normann   +33 more
core   +1 more source

Development of Prediction Models for Drug-Induced Cholestasis, Cirrhosis, Hepatitis, and Steatosis Based on Drug and Drug Metabolite Structures

Frontiers in Pharmacology, 2020
Drug-induced liver injury (DILI) is one of the major reasons for termination of drug development. Due to the importance of predicting DILI in early phases of drug development, diverse in silico models have been developed to filter out DILI-causing ...
Hyun Kil Shin, Myung-Gyun Kang, Daeui Park, Daeui Park, Tamina Park, Tamina Park, Seokjoo Yoon, Seokjoo Yoon   +7 more
doaj   +1 more source

A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity. [PDF]

, 2017
Assessing the potential of a new drug to cause drug-induced liver injury (DILI) is a challenge for the pharmaceutical industry. We therefore determined whether cell models currently used in safety assessment (HepG2, HepaRG, Upcyte and primary human ...
Aerts, H, Alexandre, E, Antherieu, S, Dorau, M, Elmasry, M, Gerets, HHJ, Goldring, CE, Hewitt, PG, Holder, JC, Hoët, D, Ingelman-Sundberg, M, Johann, E, Jones, RP, Kitteringham, NR, Labbe, G, Lauschke, VM, Lovatt, CA, Park, BK, Richert, L, Schofield, CA, Sison-Young, RL, Stahl, SH, Weaver, RJ   +22 more
core   +1 more source

Immunology Highlights of Four Major Idiosyncratic DILI Subtypes Verified by the RUCAM: A New Evidence-Based Classification

Livers
Conventionally, drug-induced liver injury (DILI) exists in two types: idiosyncratic and intrinsic. Both types are classified as non-immune disorders, thereby ignoring that some iDILI cases may have an immune or autoimmune background that requires a ...
Rolf Teschke
doaj   +1 more source

Role of High-Mobility Group Box-1 in Liver Pathogenesis [PDF]

, 2019
High-mobility group box 1 (HMGB1) is a highly abundant DNA-binding protein that can relocate to the cytosol or undergo extracellular release during cellular stress or death. HMGB1 has a functional versatility depending on its cellular location.
Huda, Nazmul, Khambu, Bilon, Yan, Shengmin, Yin, Xiao-Ming   +3 more
core   +1 more source

Pathophysiological Differences and Differential Diagnosis of Autoimmune and Drug-Induced Hepatitis

Livers
Autoimmune hepatitis (AIH) and drug-induced liver injury (DILI) are major causes of liver inflammation with distinct pathophysiology but overlapping clinical features.
Nicola Zeni, Alessandro Cristofani, Salvatore Silvio Piano, Massimo Bolognesi, Antonietta Romano   +4 more
doaj   +1 more source